Bio-Complexity: Challenging Reductionism

Chapter

Abstract

Based on the popular reductionist tradition, the advancement of molecular medicine has generated a great deal of promise. In reality, however, much of the promise will not be realized due to high levels of system complexity. The conventional wisdom is that, if we try harder, and dissect the system further by pushing new technologies, we should be able to solve most challenging heath issues, as we have overcome so much in the past. Is this belief solid and realistic? In this chapter, by introducing some typical and yet surprising cases of current medical complexity, I briefly describe key features of bio-complexity and its impact on bio-medical issues. Specifically, I will discuss the relationship between parts and the whole, the issue of system heterogeneity and stochasticity, and the importance of treating many health issues with regard to the evolutionary concept. Following the analyses of some successful and unsuccessful approaches, the key appears to be how the system status can be improved without triggering system chaos, as all medical intervention has the potential to generate system stress. Finally I call upon the need to develop more comprehensive and holistic strategies for the future of medicine, which will require a more balanced medical intervention approach.

References

  1. 1.
    Evans JP, Meslin EM, Marteau TM, Caulfield T. Deflating the genomic bubble. Science. 2011;331:861–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Heng HH. The conflict between complex systems and reductionism. JAMA. 2008;300:1580–1.PubMedCrossRefGoogle Scholar
  3. 3.
    Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRefGoogle Scholar
  4. 4.
    ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse III JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff Jr DC, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.PubMedCrossRefGoogle Scholar
  5. 5.
    ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.PubMedCrossRefGoogle Scholar
  6. 6.
    The International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52.Google Scholar
  7. 7.
    Paynter NP, Chasman DI, Paré G, Buring JE, Cook NR, Miletich JP, Ridker PM. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Heng HH. Missing heritability and stochastic genome alterations. Nat Rev Genet. 2010;11:813.PubMedCrossRefGoogle Scholar
  9. 9.
    Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ. The evolutionary mechanism of cancer. J Cell Biochem. 2010;220:538–47.Google Scholar
  10. 10.
    Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Abdallah BY, Horne SD, Ye CJ. Decoding the genome (rather than sequencing linear DNA): the next phase of genomic research. Genomics. 2011;98:242–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and a $440 billion question. J Natl Cancer Inst. 2009;101:1044–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Mittra I. The disconnection between tumor response and survival. Nat Clin Pract Oncol. 2007;4:203.PubMedCrossRefGoogle Scholar
  13. 13.
    Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Ye CJ. Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Curr Drug Targets. 2010;11:1304–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev. 2004;13:1375–84.PubMedGoogle Scholar
  15. 15.
    Heng HH, Bremer SW, Stevens JB, Liu G, Ye CJ. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res. 2011;112:217–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Collins FS, Barker AD. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am. 2007;296:50–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–99.PubMedCrossRefGoogle Scholar
  18. 18.
    Heng HH. Cancer genome sequencing: The challenges ahead. BioEssays. 2007;29:783–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Sturmberg JP. Systems and complexity thinking in general practice: part 1 - clinical application. Aust Fam Physician. 2007;36:170–3.PubMedGoogle Scholar
  20. 20.
    Heng HH. The genome-centric concept: resynthesis of evolutionary theory. Bioessays. 2009;31:512–25.PubMedCrossRefGoogle Scholar
  21. 21.
    Rancati G, Pavelka N, Fleharty B, Noll A, Trimble R, Walton K, Perera A, Staehling-Hampton K, Seidel CW, Li R. Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell. 2008;135:789–91.CrossRefGoogle Scholar
  22. 22.
    Heng HH, Chamberlain JW, Shi XM, Spyropoulos B, Tsui LC, Moens PB. Regulation of meiotic chromatin loop size by chromosomal position. Proc Natl Acad Sci U S A. 1996;93:2795–800.PubMedCrossRefGoogle Scholar
  23. 23.
    Heng HH, Goetze S, Ye CJ, Liu G, Stevens JB, Bremer SW, Wykes SM, Bode J, Krawetz SA. Chromatin loops are selectively anchored using scaffold/matrix-attachment regions. J Cell Sci. 2004;117:999–1008.PubMedCrossRefGoogle Scholar
  24. 24.
    Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol. 2009;220:538–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Davidoff F. Heterogeneity is not always noise lessons from improvement. JAMA. 2009;302:2580–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Heppner GH. Tumor heterogeneity. Cancer Res. 1984; 44:2259–65.Google Scholar
  27. 27.
    Lander ES. Initial impact of the sequencing of the human genome. Nature. 2011; 470:187–97.Google Scholar
  28. 28.
    Ye CJ, Liu G, Bremer SW, Heng HH. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res. 2007; 118:237–46.Google Scholar
  29. 29.
    Heng HH. 4D-Genomics: genome dynamics and constraint in evolution. Springer (in press).Google Scholar
  30. 30.
    Horne SD, Stevens JB, Abdallah BY, Liu G, Bremer SW, Ye CJ, Heng HH. Why imatinib remains an exception of cancer research. J Cell Physiol 2012; doi:10.1002/jcp.24233.Google Scholar
  31. 31.
    Heng HH. Elimination of altered karyotypes by sexual reproduction preserves species identity. Genome. 2007; 50: 517–524.Google Scholar
  32. 32.
    Wilkins and Holliday. The evolution of meiosis from mitosis. Genetics. 2009; 181: 2–12.Google Scholar
  33. 33.
    Gorelick R and Carpione. J. Origin and maintenance of sex: the evolutionary joys of self sex. Biol. J. Soc. 2009; 98: 707–728.Google Scholar
  34. 34.
    Gorelick R and Heng HH. Sex reduces genetic variation: a multidisciplinary review. 2011; Evolution. 64: 1088–1098.Google Scholar
  35. 35.
    Heng HH. Preface: Back to the future. Cytogenet Genome Res 2012; (in press).Google Scholar
  36. 36.
    Stevens JB, abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, Huttemann M, Taiinsky MA, Wu GS, Xie Y, Zhang K, and Heng HH. Diverse system stresses: common mechanisms of chromosome fragmentation. Cell Death and Disease. 2011; 2:e178. Doi:10.1038/cddis.2011.60Google Scholar
  37. 37.
    Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol. 2006; 208: 461–472.Google Scholar
  38. 38.
    Stevens JB, Abdallah BY, Liu G, Horne SD, Bremer SB, Ye KJ, Kurkinen M, Ye CJ, Heng HH. Heterogeneity of cell death. Cytogenet Genome Res 2012; (in press).Google Scholar
  39. 39.
    Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O’Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011 Mar 3;471(7336):68–73.Google Scholar
  40. 40.
    Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, et al. 2009 Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient. PLoS Med 2009; 6: e1000029.Google Scholar
  41. 41.
    Heng HH, Stevens J, Lawrenson L, Liu G, Ye KJ, Bremer, S and Ye, CJ. Patterns of genome dynamics and cancer evolution. Cellular Oncology 2008; 30:513–4.Google Scholar
  42. 42.
    Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, Heng HH. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol. 2009; 219: 288–300.Google Scholar
  43. 43.
    Nesse RM. Ten questions for evolutionary studies of diseases vulnerability. 2011; Evolutionary Applications 4:264–277, 2011Google Scholar
  44. 44.
    H. Gilbert Welch, Lisa Schwartz, and Steve Woloshin. 2011. Overdiagnosed: making people sick in the pursuit of health. Beacon Press.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Center for Molecular Medicine and GeneticsWayne State University School of MedicineDetroitUSA
  2. 2.Karmanos Cancer Institute, Wayne State University School of MedicineDetroitUSA
  3. 3.Department of PathologyWayne State University School of MedicineDetroitUSA

Personalised recommendations